Revance Therapeutics | Rentekostnader

Interest Expense On Debt Endring Dato
ALKERMES USD 6.01M 322K 2023-09
Eli Lilly USD 124.6M 4.3M 2023-09
Neurocrine Biosciences USD 1.1M 200K 2023-09
Pacira USD 3.39M 76K 2023-12
Supernus Pharmaceuticals USD 532K 133K 2023-12



Revance Therapeutics Rentekostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2024.